Taysha Gene Therapies Inc

$2.91

(as of Jun 3, 9:30 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Taysha Gene Therapies Inc

Stock Price

$2.91

Ticker Symbol

TSHA

Exchange

NASDAQ

Industry Information for Taysha Gene Therapies Inc

Sector

Healthcare

Industry

Biotechnology

Company Description for Taysha Gene Therapies Inc

Website

https://www.tayshagtx.com

Country

USA

Full Time Employees

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Fundamentals for Taysha Gene Therapies Inc

Market Capitalization

$529,041,920

EBITDA

$-85,376,000

Dividends per Share

P/E Ratio

Forward P/E Ratio

Earnings per Share

$-0.36

Earnings per Share Estimate Next Year

Profit Margin

Shares Outstanding

205,055,008

Percent Owned by Insiders

18.33%

Percent Owned by Institutions

82.23%

52-Week High

52-Week Low

Technical Indicators for Taysha Gene Therapies Inc

50-Day Moving Average

200-Day Moving Average

RSI

62.19

ATR

0.24

Analyst Ratings for Taysha Gene Therapies Inc

Strong Buy

Buy

Hold

Sell

Strong Sell

News About Taysha Gene Therapies Inc

Jun 4, 2025, 10:42 AM EST

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. See more.

Jun 3, 2025, 9:45 PM EST

Paul B Manning, a 10% owner of $TSHA, bought 750,000 shares of the company on 05-30-2025 for an estimated $2,062,500. See more.

Jun 3, 2025, 5:17 PM EST

Recently disclosed clinical cohort data from high (1x1015 total vg) and low dose (5.7x1014 total vg) TSHA-102 from REVEAL adolescent/adult and pediatric Phase 1/2 trials See more.

May 28, 2025, 10:40 PM EST

DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. See more.